These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1439871)

  • 21. Positron emission tomography in the investigation of central nervous system disorders.
    Jamieson D; Alavi A; Jolles P; Chawluk J; Reivich M
    Radiol Clin North Am; 1988 Sep; 26(5):1075-88. PubMed ID: 3047777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroreceptor imaging in psychiatric disorders.
    Frankle WG; Laruelle M
    Ann Nucl Med; 2002 Nov; 16(7):437-46. PubMed ID: 12508833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorodeoxyglucose PET in Neurology and Psychiatry.
    Schöll M; Damián A; Engler H
    PET Clin; 2014 Oct; 9(4):371-90, v. PubMed ID: 26050943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positron emission tomography in the investigation of neuropsychiatric disorders: update and comparison with magnetic resonance imaging and computerized tomography.
    Wegener WA; Alavi A
    Int J Rad Appl Instrum B; 1991; 18(6):569-82. PubMed ID: 1743981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography in neuropsychiatric lupus erythematosus.
    Stoppe G; Wildhagen K; Seidel JW; Meyer GJ; Schober O; Heintz P; Künkel H; Deicher H; Hundeshagen H
    Neurology; 1990 Feb; 40(2):304-8. PubMed ID: 2132733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness.
    Buchsbaum MS
    Clin Neurosci; 1995; 3(2):122-30. PubMed ID: 7583618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [PET in neurology and psychiatry I. PET with FDG in the study of the CNS].
    Montz Andrée R; Jiménez Vicioso A; Coullaut Jáuregui J; López-Ibor Aliño JJ; Carreras Delgado JL
    Rev Esp Med Nucl; 2002; 21(5):370-86; quiz 387-9. PubMed ID: 12236914
    [No Abstract]   [Full Text] [Related]  

  • 29. Controlled MRI studies in psychiatric patients--relations to functional imaging methods (EEG mapping, SPECT and PET).
    Günther W; Vogl T; Haag C; Klages U; Riedel R; Baghai T; Bscheid I; Stieg H; Moser E; Hippius H
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():116A-117A. PubMed ID: 1498775
    [No Abstract]   [Full Text] [Related]  

  • 30. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography.
    Kim JJ; Mohamed S; Andreasen NC; O'Leary DS; Watkins GL; Boles Ponto LL; Hichwa RD
    Am J Psychiatry; 2000 Apr; 157(4):542-8. PubMed ID: 10739412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroimaging in drug abuse.
    Lindsey KP; Gatley SJ; Volkow ND
    Curr Psychiatry Rep; 2003 Oct; 5(5):355-61. PubMed ID: 13678555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of radiopharmaceuticals for diagnosis of central nervous disorders.
    Kung HF
    Crit Rev Clin Lab Sci; 1991; 28(4):269-86. PubMed ID: 1930679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia.
    Bartlett EJ; Barouche F; Brodie JD; Wolkin A; Angrist B; Rotrosen J; Wolf AP
    Psychiatry Res; 1991 May; 40(1):11-20. PubMed ID: 1946838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography.
    Potkin SG; Alva G; Fleming K; Anand R; Keator D; Carreon D; Doo M; Jin Y; Wu JC; Fallon JH
    Am J Psychiatry; 2002 Feb; 159(2):227-37. PubMed ID: 11823264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropharmacological studies with SPECT in neuropsychiatric disorders.
    Heinz A; Jones DW; Raedler T; Coppola R; Knable MB; Weinberger DR
    Nucl Med Biol; 2000 Oct; 27(7):677-82. PubMed ID: 11091111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET evaluation of the dopamine system of the human brain.
    Volkow ND; Fowler JS; Gatley SJ; Logan J; Wang GJ; Ding YS; Dewey S
    J Nucl Med; 1996 Jul; 37(7):1242-56. PubMed ID: 8965206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imaging of receptors in clinical neurosciences.
    Korf J
    Acta Neurol Belg; 1997 Sep; 97(3):200-5. PubMed ID: 9345594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SPECT imaging in psychiatry: introduction and overview.
    Weinberger DR
    J Clin Psychiatry; 1993 Nov; 54 Suppl():3-5. PubMed ID: 8270596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders.
    Cervenka S
    Neurosci Lett; 2019 Jan; 691():26-34. PubMed ID: 29518542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose metabolism in psychiatric disorders: how can we facilitate comparisons among studies?
    Wiesel FA
    J Neural Transm Suppl; 1992; 37():1-18. PubMed ID: 1402849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.